Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Kazia Therapeutics Limited Announces New Preclinical Data Demonstrating the Activity of Paxalisib In 2 Forms of Childhood Brain cancer with Very High Unmet Medical Need

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Kazia Therapeutics notes this data is the subject of three abstracts presented at the Annual Meeting of the American Association for Cancer Research (AACR), held in New Orleans, LA, from April 8 – 13, 2022.

Two abstracts by scientists working in the laboratory of Assistant Professor Jeffrey Rubens at Johns Hopkins University in Baltimore, MD, describe the use of paxalisib as a backbone therapy in a childhood brain cancer known as atypical teratoid / rhabdoid tumours (AT/RT). This is the first time that data exploring paxalisib in this form of brain cancer has been presented, and it opens an important new potential indication for the drug.

The third abstract, from a different team of scientists at Johns Hopkins University, led by Associate Professor Eric Raabe and Dr Katherine Barnett, showed evidence of strong synergy between paxalisib and another class of cancer therapies in a model of diffuse intrinsic pontine glioma (DIPG). Paxalisib has previously shown evidence of activity in this disease, both as monotherapy and in combination with several types of cancer therapy, and the new data further validates its potential in this very challenging disease.

Key Points

  • AT/RT is a rare brain cancer that predominantly affects infants and young children. There are no FDA approved drugs for AT/RT and existing therapeutic options are very limited. Fewer than one in five patients survive more than two years from diagnosis.
  • Data from Professor Rubens’ laboratory shows that the PI3K pathway is commonly activated in AT/RT, and that treatment with paxalisib alone is active in preclinical models of the disease. Moreover, combination with either RG2822, an HDAC inhibitor, or TAK580, a MAPK inhibitor, appears to substantially extend survival when compared to monotherapy treatment.
  • DIPG is a rare brain cancer that is typically seen in young children and adolescents. There are no FDA approved drugs, and average life expectancy from diagnosis typically averages around ten months.
  • Previous data from several teams of researchers, and particularly from Professor Matt Dun’s team at the Hunter Medical Research Institute, has shown that paxalisib is highly active in DIPG and combines synergistically with several cancer drugs.
  • Data from Drs Raabe and Barnett and colleagues identifies an additional novel treatment combination, with the HDAC inhibitor RG2833, which exhibits evidence of strong synergy in a preclinical model of DIPG.

Kazia CEO, Dr James Garner, added, “This is very promising data, and we are grateful to the team at Johns Hopkins for this important and encouraging research. Paxalisib is already the subject of an ongoing phase II clinical trial in DIPG and diffuse midline gliomas (NCT05009992) and this new data suggests potential wider applications for the drug in childhood brain cancers. We look forward to working with the Johns Hopkins team, and with other partners and advisors, to explore these opportunities further.”

Summary of Abstracts

SESSION OPO.CL02.01 – Pediatric Cancer: Clinical Investigations

April 8, 202212:00pm-1:00pm

Abstract 5225 – The PI3K inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors
Tyler Findlay, Kristen Malebranche, Charles Eberhart, Eric Raabe, Jeffrey Rubens.
Johns Hopkins School of Medicine, Baltimore, MD

Abstract 5226 – The PI3K inhibitor Paxalisib combines synergistically with the pan-Raf inhibitor TAK580 (DAY 101) to extend survival in orthotopic xenograft models of atypical teratoid/rhabdoid tumors
Kristen Malebranche, Tyler Findlay, Charles Eberhart, Eric Raabe, Jeffrey Rubens.
Johns Hopkins School of Medicine, Baltimore, MD

SESSION PO.ET04.01 – Identification of Molecular Targets

April 13, 20229:30am-12:30pm

Abstract 3987 / 9 – Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death
Katherine Barnett, Hyuk Jean Kwon, Orlandi Novak, Charles Eberhart, Eric Raabe.
Johns Hopkins Hospital, Baltimore, MD

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine